Type of chemotherapy has substantial effects on the immune system in ovarian cancer

• Main Authors: Ann Vankerckhoven, Thaïs Baert, Matteo Riva, Christine De Bruyn, Gitte Thirion, Katja Vandenbrande, Jolien Ceusters, Ignace Vergote, An Coosemans
• Format: Article
• Language: English
• Published: Elsevier 2021-06-01
• Series: Translational Oncology
• Subjects: Ovarian cancer; Chemotherapy; MDSC; Carboplatin-paclitaxel; Immunosuppression
• Online Access: http://www.sciencedirect.com/science/article/pii/S1936523321000681

Chemotherapy induces a variety of immunological changes. Studying these effects can reveal opportunities for successful combining chemotherapy and immunotherapy. Immuno-chemotherapeutic combinations in ovarian cancer are currently not generating the anticipated positive effects. To date, only scattered and inconsistent information is available about the immune-induced changes by chemotherapy in ovarian cancer. In this study, we compared six common chemotherapeutics used in ovarian cancer patients (carboplatin, paclitaxel, pegylated liposomal doxorubicin, gemcitabine, carboplatin-paclitaxel and carboplatin-gemcitabine) and studied their effects on the immune system in an ovarian cancer mouse model. Mice received a single chemotherapy or vehicle injection 21 days after tumor inoculation with ID8-fluc cells. One week after therapy administration, we collected peritoneal washings for flow cytometry, serum for cytokine analysis with cytometric bead array and tumor biopsies for immunohistochemistry. Carboplatin-paclitaxel showed the most favorable profile with a decrease in immunosuppressive cells in the peritoneal cavity and an increase of interferon-gamma in serum. In contrast, carboplatin-gemcitabine seemed to promote a hostile immune environment with an increase in regulatory T-cells in tumor tissue and an increase of macrophage-inflammatory-protein-1-beta in the serum.